Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC).

Autor: Loeser AL; Patient-Centered Dosing Initiative, Salt Lake City, UT, USA., Gao L; Yale School of Medicine, New Haven, CT, USA. lgao11@partners.org., Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Burkard ME; University of Wisconsin Carbone Cancer Center, Madison, WI, USA., Kalinsky KM; Winship Cancer Institute at Emory University, Atlanta, GA, USA., Peppercorn J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Rugo HS; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA., Carlson M; Patient-Centered Dosing Initiative, Salt Lake City, UT, USA., Cowden J; Patient-Centered Dosing Initiative, Salt Lake City, UT, USA., Glenn L; Patient-Centered Dosing Initiative, Salt Lake City, UT, USA., Maues J; Patient-Centered Dosing Initiative, Salt Lake City, UT, USA., McGlown S; Patient-Centered Dosing Initiative, Salt Lake City, UT, USA., Ni A; Division of Biostatistics, Ohio State University, Columbus, OH, USA., Padron N; Patient-Centered Dosing Initiative, Salt Lake City, UT, USA., Lustberg M; Smilow Cancer Hospital, Yale Cancer Center, New Haven, CT, USA.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2022 Dec; Vol. 196 (3), pp. 549-563. Date of Electronic Publication: 2022 Oct 06.